KRAS and non-small cell lung carcinoma: Next, 37.0% (210/567) of patients with primary diagnosed ACA in the early stages, I–IIIA, displayed genomic driver alterations that could be targeted by TKI therapies currently approved in advanced NSCLC (EGFR, KRAS G12C, BRAF V600E, ERBB2, ALK, ROS1, METEx14skip, RET).